Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic L
- PDF / 234,958 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 83 Downloads / 178 Views
CORRECTION
Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis Kyle Fahrbach . Jialu Tarpey . Evelien Bergrath Washington . Rachel Hughes . Howard Thom . Maureen P. Neary . Amy Cha . Robert Gerber . Joseph C. Cappelleri
Ó The Author(s) 2020
Correction to: Dermatol Ther (Heidelb) (2020) 10:681–694 https://doi.org/10.1007/s13555020-00389-5 The authors would like to replace 2 small sections of the published manuscript that refer to a The original article can be found online at https://doi. org/10.1007/s13555-020-00389-5. K. Fahrbach J. Tarpey E. B. Washington (&) R. Hughes Evidence Synthesis, Modeling & Communication, Evidera, Waltham, MA, USA e-mail: [email protected] H. Thom Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK H. Thom Clifton Insight, Bristol, UK M. P. Neary Inflammation and Immunology, Pfizer Inc., Collegeville, PA, USA A. Cha Inflammation and Immunology, Pfizer Inc., New York, NY, USA R. Gerber Inflammation and Immunology, Pfizer Inc., Groton, CT, USA J. C. Cappelleri Global Biometrics and Data Management (Statistics), Pfizer Inc., Groton, USA
qualitative review of safety data for included studies (together with an associated safety table), to provide some further clarifications on these safety data and to include some quantitative updates for rates. Specifically, the authors would like to replace the paragraph under the ‘‘Overall Adverse Events’’ section of the paper with text provided below, which includes edits to be consistent with updated rates in Kempers paper [28] that are provided in the updated Table 1 below. Overall Adverse Events The rates of overall AEs ranged from 15.4% [26] to 86.0% [28]. The rates of patients reporting at least one treatment-emergent AE with crisaborole (29.3% and 29.4%) were similar to the rates experienced in the vehicle group (19.8% and 32.0%) [14]. Rates of overall AEs reported for tacrolimus, 0.03%, ranged from 15.4% [26] to 84.0% [28] across three RCTs, and for tacrolimus, 0.1%, was 32.7% in one RCT [27]. These rates were 16.6% [26] to 86.0% [28] for pimecrolimus across three RCTs. Additionally, the authors would like to replace the paragraph under the ‘‘Common Adverse Events’’ section of the paper with the text below in order to include clarifications regarding the updated MedDRA term for application site pain that was used in the crisaborole studies, however, this was not used in the studies for comparator agents.
Dermatol Ther (Heidelb)
Table 1 Qualitative summary of safety data of included trials Author, year (trial name)
Intervention/comparator Adverse eventsa, n/N (%)
Paller 2016 (AD-301) [14]
Crisaborole, 2%
Overall
Application site
URTI
Skin infection
Erythema
TEAE: 147/502 (29.3)
Reaction: 48/502 (9.6)
14/502 (2.8)
Staphylococcal: 0/502 (0)
Application site: 2/502 (0.4)
TEAE: 50/252 (19.8)
Reaction: 12/252 (4.8)
10/252 (4.0)
Staphylococcal: 1/252 (0.4)
Appli
Data Loading...
